Seattle Genetics said Tuesday it has initiated a 60-patient clinical trial of an experimental cancer therapy for chronic lymphocytic leukemia...
Seattle Genetics said Tuesday it has initiated a 60-patient clinical trial of an experimental cancer therapy for chronic lymphocytic leukemia (CLL).
SGN-40, a genetically engineered monoclonal antibody, is already being studied for multiple myeloma and non-Hodgkin’s lymphoma in other early trials.
The Bothell company also said SGN-40 received “orphan drug” designation for CLL from the Food and Drug Administration. The designation, for treatment of relatively rare diseases, means Seattle Genetics will have seven years of market exclusivity if the drug is approved.
The company’s stock lost 8 cents, or 1.6 percent, to close at $4.93 Tuesday. It fell 3 more cents in after-hours trading.
Most Read Stories
- Please go fishing, Washington state says after farmed Atlantic salmon escape broken net
- Seattle-based crab boat found on Bering Sea bottom; lost since February with crew of 6
- What caused Seattle-based crab boat to sink with 6 aboard? Coast Guard hoping to find out
- Lost Seattle-based crab-boat crew memorialized VIEW
- Police: Elderly Seattle brothers spent lifetime collecting sexual images of children, sexually abusing young girls